
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst Inc. is expected to maintain high single-digit organic growth in the future driven by the acquisition of new clients and contractual price adjustments, with a focus on achieving a long-term margin expansion target of 20%. The company reported better-than-expected fourth-quarter results, which reflects positive traction with its Ignite platform and an overall improving profitability outlook. Additionally, opportunities for value creation exist through asset monetization, such as VitalWare, which could provide a path forward amidst current challenges in its core data infrastructure platform.
Bears say
Health Catalyst Inc. is facing several challenges that could impact its financial performance negatively, as indicated by its recent third-quarter results and outlook for 2026. The company is reporting a decline in organic revenue and has lowered future revenue guidance, anticipating a 2-3% year-over-year decrease, reflecting headwinds from client migrations to a lower-cost platform and general economic uncertainty. Additionally, guidance for the first quarter of 2026 shows significant year-over-year revenue declines, coupled with disappointing adjusted EBITDA projections, highlighting concerns regarding customer attrition and the overall health of the purchasing environment for its services.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares